A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

Parkinson Disease Clinical Trial

Official title:

A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05258071
• Other study ID #: IRL752C003
• Status: Recruiting
• Phase: Phase 2
• Start date: June 15, 2022
• Est. completion date: January 2025

Study information

• Verified date: April 2024
• Source: Integrative Research Laboratories AB
• Contact: Joakim Tedroff
• Phone: +46707601691
• Email: joakim.tedroff[@]irlab.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.

Description:

At the screening visit consenting patients will be screened for eligibility according to study specific inclusion/exclusion criteria within 6 weeks before start of Investigational Medicinal Product (IMP) administration. Patients will be asked to complete a fall diary for at least 4 consecutive weeks during the screening period and to be eligible for randomization, the patient should have experienced at least 2 falls during the 4 weeks preceding the baseline visit. At the baseline visit, patients will be randomized to receive one of two doses of Pirepemat (dose 1 or dose 2) or placebo t.i.d. (1:1:1). Dosing will start with half the dose for the first week of treatment and then continue with full dose until Week 11. Dosing will be de-escalated according to pre-specified schedule during the last week of study treatment, ending with the last dose on Day 84. The treatment allocation will be double-blind, i.e. it will not be disclosed to the patients, the site staff or the Sponsor. During the treatment period, patients will capture falls at home using a fall diary and changes in cognitive, postural, motor and mental functions will be assessed using the Montreal Cognitive Assessment (MoCA), Movement Disorder Society - Unified Parkinson´s Disease Rating Scale (MDS-UPDRS), Neuropsychiatric Inventory (NPI) (Apathy/Indifference part), Single Leg Stance Test, Tandem walking test, and Clinician's Global Impression of Severity (CGI-S) and Improvement (CGI-I). Blood samples for pharmacokinetic (PK) analysis will be collected at visit 5 (week 6) and visit 8 (week 11). Following the last IMP dose, a safety follow-up period (including laboratory assessments at 3 instances) of approximately 1 month will take place.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 165
• Est. completion date: January 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Male or female 55-85 years of age, inclusive.

2. Diagnosis of idiopathic Parkinson's disease, according to the UK Parkinson's disease Society Brain Bank criteria.

3. Montreal Cognitive Assessment (MoCA) score of =10 and <26 at screening.

4. A modified Hoehn & Yahr score of =2.5 in "on".

5. Having experienced recurrent falls during the past 3 months (based on interview with the patient and/or caregiver) and at least 2 falls during the past 4 weeks before baseline.

6. On a stable regimen of anti-Parkinson's medications for at least 30 days prior to baseline, and willing to continue the same doses and regimens during study participation.

7. Able to cooperate and participate in study related procedures. This includes the ability to accurately complete a fall diary. The fall diary may also be completed by a responsible caregiver. For patients meeting DSM-IV TR criteria for Parkinson's disease dementia, the fall diary should be completed by the caregiver.

8. Availability of a responsible caregiver at least five days per week at least 2 hours per day. For patients meeting DSM-IV TR criteria for Parkinson's disease dementia, availability of a responsible live-in caregiver is required.

9. Female patients must be of non-childbearing potential (defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or post-menopausal females defined as 12 months of amenorrhoea [in questionable cases a blood sample with simultaneous follicle stimulation hormone (FSH) 25-140 IE/L and oestradiol <200 pmol/L is confirmatory]).

10. Fertile male patients must be willing to use condom and refrain from donating sperm during the study and until 3 months after last dosing of IMP and ensure that their fertile female partners are using contraceptive methods to prevent pregnancy .

11. Written informed consent for participation in the study given by the patient and the responsible caregiver.

Exclusion Criteria:

1. Any of the following potential hepatic conditions:

1. known history of alcohol abuse, chronic liver or biliary disease, with the exception of Gilbert's syndrome

2. total bilirubin greater than the upper limit of the normal range (unless associated with isolated instances of suspected Gilbert's syndrome)

3. alkaline phosphatase (ALP) greater than 1.5 times the upper limit of the normal range

4. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2 times the upper limit of the normal range

5. history of repeated unexplained upper right quadrant abdominal pain and/or nausea, or jaundice

2. A positive Hepatitis B surface antigen or a positive Hepatitis C antibody result.

3. A score of 5 (wheelchair bound or bedridden) in the "on"-state on the modified Hoehn & Yahr scale.

4. Uncontrolled symptomatic orthostatic hypotension.

5. Clinically significant polyneuropathy.

6. Weight <55 kg at Screening.

7. Patients with current or past treatment with deep brain stimulation (DBS) or patients with previous history of stereotaxic brain surgery for PD.

8. A current diagnosis of any primary neurodegenerative disorder other than idiopathic PD.

9. A current diagnosis of any treatable dementia (hypothyroidism, syphilis, vitamin B12 or folate deficiency) that is verified by the investigator to be the cause of dementia.

10. A current diagnosis of a major depressive episode according to DSM-IV criteria.

11. Patient has delirium.

12. Any history of a heart condition, including prolonged QTc (>450 ms for males and > 470 ms for females, QTcF and/or QTcB), cardiac arrhythmias, any repolarisation deficits or any other clinically significant abnormal ECG as judged by the Investigator.

13. Severe or ongoing unstable medical condition including a history of poorly controlled diabetes; obesity associated with metabolic syndrome; uncontrolled hypertension; cerebrovascular disease, or any form of clinically significant cardiac disease; renal failure, history of abnormal renal function.

14. History of seizures within two years of screening.

15. History of cancer within five years prior to screening, with the following exceptions:

adequately treated non-melanomatous skin cancers, localised bladder cancer, non-metastatic prostate cancer or in situ cervical cancer.

16. History of severe allergy/hypersensitivity or on-going allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to pirepemat.

17. Creatinine clearance <30 mL/min (calculated according to the Cockroft-Gault formula).

18. Treatment with Warfarin within three months before study treatment.

19. Treatment with Amantadine within 6 weeks before study treatment.

20. Treatment with Selegiline within 6 weeks before study treatment.

21. Administration of another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment with less than three months between administration of last dose and first dose of IMP in this study.

22. Current or history of drugs of abuse according to DSM-IV criteria.

23. Any planned major surgery within the duration of the study.

24. Any other condition or symptoms preventing the patient from entering the study, according to the Investigator's judgement.

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Drug:
• Pirepemat
Oral use
• Placebo
Oral use

Locations

Country	Name	City	State
France	Hôpital Neurologique Pierre Wertheimer	Bron
France	Hopital de la Timone	Marseille
France	Hôpital Laennec - Centre d'investigation clinique de Neurologie	Nantes
France	CHU Charles Nicolle	Rouen
France	CHU Toulouse - Hôpital Purpan	Toulouse
Germany	Charite Universitatsmedizin Berlin - Klinik fuer neurologie mit experimenteller neurologie	Berlin
Germany	Klinik für Neurologie - Alexianer St. Joseph-Krankenhaus	Berlin
Germany	Praxis Dr.med. Christian Oehlwein Facharzt für Neurologie und Psychiatrie	Gera
Germany	Universitätsmedizin Göttingen - Klinik für Neurologie	Göttingen
Germany	Klinische Forschung Hamburg GmbH	Hamburg
Germany	Universitaetsklinikum Leipzig - Klinik und Poliklinik fuer Neurologie	Leipzig
Germany	Philipps-Universitaet Marburg	Marburg
Germany	Kliniken Kreis Muehldorf a. Inn	Mühldorf
Germany	Universitysklinikum Münster - Klinik für neuroligie	Münster
Germany	Klinische Forschung Schwerin GmbH	Schwerin
Germany	RKU - Universitäts- und Rehabilitationskliniken Ulm Klinik für Neurologie	Ulm
Netherlands	Radboud Universitair Medisch Centrum (Radboudumc)	Nijmegen
Poland	Silmedic sp. z o.o	Katowice
Poland	Pratia MCM Krakow	Krakow
Poland	Diamond Clinic sp. z o.o.	Kraków
Poland	Krakowska Akademia Neurologii Sp. z o.o.	Kraków
Poland	ETYKA Osrodek Badan Klinicznych	Olsztyn
Poland	Instytut Zdrowia	Oswiecim
Poland	Centrum Medyczne HCP SP Z OO	Poznan
Poland	Neuro-Care Clinic	Siemianowice Slaskie
Poland	RCMed	Sochaczew
Poland	Centrum Medyczne NeuroProtect	Warszawa
Poland	Singua Sp. z o.o.	Warszawa
Spain	Hospital Clinic Barcelona	Barcelona
Spain	Hospital de Sant Pau	Barcelona
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital General Universitario de Elche	Elche
Spain	Hospital Infanta Sofia	Madrid
Spain	Hospital Universitario del Henares	Madrid
Spain	Clinica Universitaria de Navarra	Pamplona
Sweden	Institute of Neuroscience and Physiology	Göteborg
Sweden	Skane University Hospital - Division of Neurology	Lund
Sweden	Karolinska Universitetssjukhuset - Neurologiska kliniken	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Integrative Research Laboratories AB

Countries where clinical trial is conducted

France,  Germany,  Netherlands,  Poland,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in falls frequency with Pirepemat compared to placebo as assessed with fall diary from baseline period (4 weeks prior to randomization) to the end of treatment.	Falls being recorded using a paper fall diary (Patient Reported Outcome, PRO)	Baseline to end of treatment (week 12)
Secondary	Change in the total score of MDS-UPDRS part 2 (M-EDL) from baseline to end of full dose treatment (with pirepemat compared to placebo).	The total scoring range is 0-52, where a higher score indicates more severe impact on Motor Aspects of Experiences of Daily Living (M-EDL).	Baseline to end of full dose treatment (week 11)
Secondary	Change in total score (Frequency*Severity) of NPI Item G (Apathy/Indifference) from baseline to end of full dose treatment (with pirepemat compared to placebo).	The total scoring range is 1-12, where a higher score indicates a higher degree of apathy/indifference.	Baseline to end of full dose treatment (week 11)
Secondary	Change in Caregiver distress of NPI Item G (Apathy/Indifference) from baseline to end of full dose treatment (with pirepemat compared to placebo).	The total scoring range is 0-5, where a higher score indicates a more severe caregiver distress.	Baseline to end of full dose treatment (week 11)